LI Qing. On the Perfection of China's Pharmaceutical Patent Linkage System[J]. Journal of Southwest Petroleum University(Social Sciences Edition), 2021, 23(6): 41-48.
[1] C Scott Hemphill, Mark A Lemley. Earning Exclusivity:Generic Drug Incentives and the Hatch-Waxman Act[J]. Antitrust Law Journal, 2011(3):947-989. [2] 丁锦希, 郭璇.中美药品上市审批过程中的专利链接问题研究[J].中国卫生法制, 2011(5):21-28. [3] Rebecca S Eisenberg, Daniel A Crane. Patent punting:how FDA and antitrust courts undermine the hatch-waxman act to avoid dealing with patents[J]. Michigan Telecommunications and Technology Law Review. 2015(2):197-262. [4] Shashank Upadhye. Generic pharmaceutical patent and FDA law[M]. Minneapolis, Thomson West, 2015:519-520. [5] Martin A Voet. The generic challenge:understanding patents, FDA and pharmaceutical life-cycle management[M]. Boca Raton, Brown Walker Press, 2016:116. [6] 郑淑凤.专利链接中拟制侵权的理论基础与实施问题[J].电子知识产权, 2019(12):83-94. [7] Shashank Upadhye. Understanding patent infringement under 35 U.S.C.271(e):the collisions between patent[J]. Santa Clara computer and high-technology law journal, 2001(1):1-66. [8] Pamela Fitch. Patent Linkage Bill[EB/OL]. (2013-06-20)[2020-12-08]. http://www.villaseca.cl/English/Noticias/2013/Noticias_jun_2013.html. [9] Jeong Seung Joo, Patent-Drug Approval Linkage in korea under korea-U.S. FTA-Based on Comparative study on U.S. Hatch-Waxman Act and canadian patented medicines(Notice of compliance) regulation[J]. Munich Intellectual Property Law Center Master Thesis, 2013(2):1-80. [10] 王立达, 陈蔚奇.仿制药上市审查之专利连结制度:从美国经验检证其存立基础与制度设计[J].台大法学论丛, 2010(4):351-405. [11] Ronald A Bouchard et al.Structure-function analysis of global pharmaceutical linkage regulations[J]. Minnesota Journal of Law, Science & Technology, 2011(2):392-454. [12] Generic Medicines Industry Association. Key facts you need to know about generic medicines in australia[EB/OL].(2014-02-15)[2020-12-08]. http://www.gmia.com.au/wp-content/uploads/2014/02/GMiA-Fact-Sheet-Summary.firefox.pdf. [13] Alyssa L Brown. Modest proposals for A complex problem:patent misuse and incremental change to the hatch-waxman ACT as solutions to the problem of reverse payment settlement[J]. University of Baltimore Law Review, 2012(3):583-613.